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VE Networks: Methods
Methods
Design: Test-negative design 
 Comparing odds of laboratory-confirmed influenza among vaccinated vs. 
unvaccinated patients
 Vaccination status: receipt of one dose (≥1 dose for children 6m-8 years) of any 
2018–19 seasonal flu vaccine at least 14 days prior to illness onset
 Sources: Medical records, immunization registries, and/or self-report (self-report 
only for inpatient networks)
Analysis:  VE = (1 – adjusted OR) x 100%
 Adjustment for potential confounding variables (i.e. study site, age, calendar 
time)
US Flu VE HAIVEN NVSN
Enrollment period Nov 23-May 3 Nov 2-May 3 Nov 7-May 13
Enrolled 10,041 2,873 1,481
Influenza pos (%) 2,795(28%) 461(16%) 190(13%)
Equal distribution of H1N1 and H3N2 in all networks
721/786 (92%) of H3 
viruses were 3C.3a
85/93 (91%) of H3 
viruses were 3C.3a
A(H3N2), 
50%A(H1N1)
pdm09 , 
45%
A, unsubtyped , 4% B/Yamagata, 
1%
Ambulatory settings – all ages
US Flu VE Network
US Flu VE Network:  Number of enrolled participants by 
influenza RT-PCR result and percent positivity by week of onset
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Adjusted vaccine effectiveness against medically attended 
influenza by age group, US Flu VE Network, 2018–19
Vaccine Effectiveness
Influenza positive Influenza negative Unadjusted Adjusted*
Any influenza 
A or B virus
N vaccinated
/Total (%)
N vaccinated
/Total (%) VE % 95% CI VE % 95% CI
Overall 1333/2795 48 4059/7246 56 28 (21 to 34) 29 (21 to 35)
Age group (yrs)
6 mos–8 303/759 40 977/1675 58 53 (43 to 60) 49 (38 to 58)
9–17 221/493 45 319/772 41 -15 (-45 to 8) 6 (-22 to 27)
18–49 323/831 39 1074/2435 44 19 (5 to 31) 25 (10 to 37)
50–64 271/448 60 827/1324 62 8 (-15 to 26) 12 (-12 to 31)
≥65 215/264 81 862/1040 83 9 (-29 to 36) 12 (-29 to 41)
* Multivariable logistic regression models adjusted for site, age, sex, race/ethnicity, self-rated general health status, interval from onset to enrollment, 
and calendar time.
Adjusted vaccine effectiveness* against medically attended 
influenza by age group, US Flu VE Network, 2018–19
* Multivariate logistic regression models adjusted for site, age, sex, race/ethnicity, self-rated general health status, interval from onset to enrollment, and 
calendar time.
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Adjusted vaccine effectiveness* against medically attended 
influenza by virus subtype, US Flu VE Network, 2018–19
* Multivariable logistic regression models adjusted for site, age, sex, race/ethnicity, self-rated general health status, interval from onset to enrollment, 
and calendar time.
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Adjusted vaccine effectiveness against influenza A/H3N2 by 
clade, US Flu VE Network, 2018–19 (seq. data as of 6/21/19)
Vaccine Effectiveness
Influenza positive Influenza negative Unadjusted Adjusted*
N vaccinated
/Total (%)
N vaccinated
/Total (%) VE % 95% CI VE % 95% CI
All Influenza A/H3N2
All H3N2 710/1352 53 4065/7249 56 13 (3 to 23) 9 (-4 to 20)
Sequenced H3N2 404/773 52 4065/7249 56 14 (1 to 26) 15 (-1 to 28)
A(H3N2) clade 3C.3a 372/709 52 4065/7249 56 14 (-1 to 26) 11 (-6 to 26)
A(H3N2) clade 3C.2a1 30/61 49 4065/7249 56 24 (-25 to 54) 45 (5 to 68)
* Multivariable logistic regression models adjusted for site, sex, race/ethnicity, self-rated general health status, interval from onset to enrollment, and 
calendar time.
Hospitalized Adult Influenza Vaccine 
Effectiveness Network (HAIVEN) 
preliminary results
Adjusted vaccine effectiveness against influenza, by age group 
and virus subtype, HAIVEN, 2018–19 (n=2810)
Vaccine Effectiveness
Influenza positive Influenza negative Unadjusted Adjusted*
Any influenza 
A or B virus
N vaccinated
/Total (%)
N vaccinated
/Total (%) VE % 95% CI VE % 95% CI
Overall 307/474 65 1615/2336 69 18 (-1 to 33) 25 (1 to 41)
By age group
18-49 yr 52/95 55 281/500 56 6 (-46 to 39) 1 (-58 to 38)
50-64 yr
>65 yr
76/152
179/227
50
79
518/809
816/1027
64
79
44
4
(20 to 60)
(-37 to 32)
47
15
(22 to 63)
(-24 to 41)
By virus subtype
H3N2 183/234 78 1615/2336 69 -60 (-121 to -16) -43 (-102 to -2)
H1N1pdm09 107/213 50 1615/2336 69 55 (40 to 66) 60 (46 to 71)
*Adjusted for study site, age, race/Hispanic ethnicity, days from illness onset to respiratory specimen collection, calendar time of illness onset, home oxygen 
use, immunosuppressive conditions/medication(s), and number of self-reported hospitalizations in the prior year
Inpatient Pediatric VE – 6 months to 17 
years
NVSN preliminary results
Adjusted vaccine effectiveness against pediatric influenza 
hospitalization, by patient age/virus subtype, NVSN, 2018–19
Vaccine Effectiveness
Influenza positive Influenza negative Unadjusted Adjusted*
N vaccinated
/Total (%)
N vaccinated
/Total (%) VE % 95% CI VE % 95% CI
Any influenza A or B virus
Overall 80/190 42 646/1291 50 27 (1 to 47) 31 (5 to 51)
By age group
6 mo to 8 yr 64/142 45 553/1119 49 16 (-19 to 41) 26 (-6 to 49)
9 to 17 yr 16/48 33 93/172 54 57 (16 to 78) 53 (5 to 77)
By virus subtype
H3N2 50/105 48 646/1291 50 9 (-35 to 39) 13 (-31 to 43)
H1N1pdm09 26/73 36 646/1291 50 44 (9 to 66) 48 (14 to 68)
*Multivariable logistic regression models adjusted for age, study site, and calendar time (month of enrollment)
Discussion
Interpreting VE estimates for influenza A(H3N2)
 Three US networks identified no vaccine protection against predominant 
H3N2 virus this season, consistent with laboratory data on 3C.3a clade  
 Negative VE for H3N2 in adult inpatient network (HAIVEN) based on small 
number of cases and could be related to chance or bias
–
–
–
Findings are “unstable” in that they are subject to changes with small alterations in case 
or vaccine classification
No similar finding using an alternative control group (VE was no longer negative when 
using RSV-positive comparison group), suggesting bias 
No similar findings of increased influenza vaccination rates in cases from other US 
platforms (US Flu VE Network or US FluSurvNet) compared to HAIVEN
 Cannot exclude possibility of alternative biological explanations
Next steps for finalizing VE estimates
 Updated data, vaccine verification and analysis
–
–
–
Review of preliminary data: no issues identified related to data miscoding or analysis
Data extraction (underlying conditions) ongoing
Verification of vaccination status, prior vaccination history, and vaccine type 
 Evaluate serologic specimens and virus sequencing (US Flu VE and HAIVEN)
 Collaborating with partners to compare findings in other networks and consider 
possible explanations 
 Update to ACIP Influenza Working Group early fall 2019 
Summary
 Overall VE was ~30% against influenza illness and hospitalizations. 
• Vaccine likely prevented between  ~40,000 to 90,000 hospitalizations 
based on previous seasons’ estimates
 Vaccine reduced A(H1N1)pdm09- associated outpatient influenza illness 
by 44% and hospitalizations by 48%-60%
 No significant protection against H3N2 illnesses likely due to emergence of 
antigenically different A(H3N2) clade 3C.3a 
• WHO has updated the A(H3N2) component of 2019-2020 Northern 
Hemisphere influenza vaccines 
 These VE estimates are preliminary and will be updated when final data 
are available
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